LV10459B - Corticued-17-alkylcarbonates, substituted in the 17-position, process for their preparation and pharmaceuticals containing them - Google Patents
Corticued-17-alkylcarbonates, substituted in the 17-position, process for their preparation and pharmaceuticals containing them Download PDFInfo
- Publication number
- LV10459B LV10459B LVP-93-302A LV930302A LV10459B LV 10459 B LV10459 B LV 10459B LV 930302 A LV930302 A LV 930302A LV 10459 B LV10459 B LV 10459B
- Authority
- LV
- Latvia
- Prior art keywords
- formula
- prednisolone
- compound
- hydrogen
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
- C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
- C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Claims (3)
- Patentformulas punkti 1. Ķ2EĪiķ2ī^y_lZlĒļķiļ^E^2Q^is ar kopējo formulu (I) CH2-R(1) coz kurā: A ir CHOH jebkurā stēriskā rindā, CH^, C=0; Y ir ūdeņradis, fluors vai hlors; Z ir ūdeņradis, fluors vai metilgrupa; R(1) ir F, Cl, Br, I, 0~acilgrupa ar formulu (II): (II) -O-CO-(CH„) -R(4) 2 n vai oksikarboniloksialkilgrupa ar formulu (III): -0-C0-0-(CH„) -R(4) (III) Z n vai alkilsulfonāts vai arilsulfonāts ar formulu (IV): -0-S02-R(5) (IV) kur R(4) ir ūdeņradis, Cj_jQ-alkilgrupa, C^g-cikloalkil-grupa, vai, ja n = 1, ir fluors, hlors vai broms; R(5) ir C^^-alkilgrupa, fenilgrupa, hlorfenilgrupa vai metilfenil-grupa; n ir vesels skaitlis no 0 līdz 4; R(2) ir sazarota C3_g-alkilgrupa vai -(CH,,^_^-0CH3; un R(3) ir ūdeņradis vai alfa-metilgrupa. 2. Ķ2E£iķ2Ī^H_lZl§ļ!Sļļķ§EĪĪ25!i§ pēc punkta 1, kurā: R(l), A, Y, Z, R(3) un R(4) ir ar punktā 1 minētajām nozīmēm, un R(2) ir sazarota C3_5~alkilgrupa vai -(CH2)-0CH3 iin R(5) ir metilgrupa, etilgrupa, propilgrupa vai para stāvoklī ar hloru vai metilgrupu neobligāti aizvietota fenilgrupa.
- 3. Paņēmiens savienojuma (I) pēc punkta 1 iegūšanai, kas ietver savienojuma ar formulu (V)LV 10459 hidrolizēšanu ar vāju skābi un iegūtā 21-hidroksi atvasinājuma ar formulu (I), kur R(1) ir OH, esterificēšanu ar karbonskābes (VI) halogenīdu vai anhidrīdu R(4)-(CH)-C00H (VI) vai ar halogenformiātu (VII) R(4)-(CHg)-oCO-ha1ogēns (VII) vai ar sulfonilhalogenīdu (VIII) R(5)-S02-halogēns (VIII) un, ja vēlams, iegūto 21-sulfoskābes esteru reakciju ar halogēnīdu sāļiem, veidojot 21-halogenīdus ar formulu (I), kurā R(l) ir hlors, broms, jods vai fluors. 4. P§Sl5!i®DĒ savienojuma (V) iegūšanai ?H2 CO°\-° ^0R(2)'*(3) (V) kas ietver savienojuma (Vļ) CH2-OH c «= okurā A, Y, Z, R(3) un saites 2---1 nozīmes atbilst punktā 1 dotajām, apstrādi ar tetraalkilortokarbonātiem (Vil), kuru alkilgrupas ir sazarotas vai aizvietotas (Vil) \ R(6) C OCH R(7) kur: R(6) ir H vai CH^ un R(7) ir CH3, CH(CH3)2, C(CH3)3 vai CH20CH3t ar noteikumu, ka R(6) nav ūdeņradis, ja R(7) satur nesazarotu oglekļa atomu ķēdi, O _ o inertos šķīdinātājos pie temperatūras virs 20 C un līdz 120 C, veļams, pie reakcijas maisījuma viršanas temperatūras, jo sevišķi pie 50 - 60 °C. LV 10459 5. Ārstniecības līdzeklis dermatožu ārstēšanai, sevišķi iekaisumu un alerģisko dermatožu ārstēšanai, kas satur efektīvu daudzumu savienojuma (I) pēc punkta 1, 6. dermatožu ārstēšanai, kas paredz cietušā ādas rajona apstrādi ar efektīvu daudzumu savienojuma (I) pēc punkta 1, kas sajaukts ar parasti farmācijā lietotajām piedevām.
- 7. Savienojuma (I) pēc punkta 1 pielietojums tāda ārstniecības līdzekļa ražošanai, kas paredzēts dermatožu ārstēšanai.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4025342A DE4025342A1 (de) | 1990-08-10 | 1990-08-10 | In 17-stellung substituierte corticoid-17-alkylcarbonate, verfahren zu deren herstellung und diese enthaltende arzneimittel |
Publications (2)
Publication Number | Publication Date |
---|---|
LV10459A LV10459A (lv) | 1995-02-20 |
LV10459B true LV10459B (en) | 1995-08-20 |
Family
ID=6411982
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LVP-93-302A LV10459B (en) | 1990-08-10 | 1993-05-07 | Corticued-17-alkylcarbonates, substituted in the 17-position, process for their preparation and pharmaceuticals containing them |
Country Status (22)
Country | Link |
---|---|
US (1) | US5362721A (lv) |
EP (1) | EP0470617A3 (lv) |
JP (1) | JPH0641187A (lv) |
KR (1) | KR920004407A (lv) |
AU (1) | AU646066B2 (lv) |
CA (1) | CA2048841A1 (lv) |
CZ (1) | CZ279875B6 (lv) |
DE (1) | DE4025342A1 (lv) |
EC (1) | ECSP941049A (lv) |
EG (1) | EG19928A (lv) |
FI (1) | FI913775A (lv) |
HU (1) | HU211994B (lv) |
IE (1) | IE912827A1 (lv) |
IL (1) | IL99135A (lv) |
LT (1) | LT3374B (lv) |
LV (1) | LV10459B (lv) |
MX (1) | MX9100613A (lv) |
NO (1) | NO913115L (lv) |
PT (1) | PT98605A (lv) |
RU (1) | RU2060997C1 (lv) |
TW (1) | TW203056B (lv) |
ZA (1) | ZA916291B (lv) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4328819A1 (de) * | 1993-08-27 | 1995-03-02 | Hoechst Ag | Corticosteroid-17-alkylcarbonat-21/0/-Carbonsäure- und Kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
DE4333920A1 (de) | 1993-10-05 | 1995-04-13 | Hoechst Ag | Corticoid-17,21-dicarbonsäureester sowie Corticosteroid-17-carbonsäureester-21-kohlensäureester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel |
US5981517A (en) * | 1996-05-09 | 1999-11-09 | Soft Drugs, Inc. | Androstene derivatives |
US6858596B2 (en) * | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
US6759398B2 (en) * | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
GB0019172D0 (en) | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
SK287576B6 (sk) | 2000-08-05 | 2011-03-04 | Glaxo Group Limited | S-fluórmetylester kyseliny 6alfa, 9alfa-difluór-17alfa-[(2- furanylkarboxyl)oxy]-11beta-hydroxy-16alfa-metyl-3-oxo-androsta- 1,4-dién-17beta-karbotiovej, spôsob jeho prípravy, farmaceutický prostriedok s jeho obsahom, jeho použitie a medziprodukty |
US6777399B2 (en) * | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
AR033290A1 (es) * | 2001-04-30 | 2003-12-10 | Glaxo Group Ltd | Derivados antiinflamatorios de androstano |
WO2002100879A1 (en) * | 2001-06-12 | 2002-12-19 | Glaxo Group Limited | Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives |
US20050175545A1 (en) * | 2002-02-04 | 2005-08-11 | Keith Biggadike | Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist |
GB0202635D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Wellcome Mfg Pte Ltd | Formulation containing novel anti-inflammatory androstane derivative |
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
ATE426610T1 (de) * | 2005-02-04 | 2009-04-15 | Us Gov Health & Human Serv | Nandrolon-17ss-carbonate |
GB0507165D0 (en) * | 2005-04-08 | 2005-05-18 | Glaxo Group Ltd | Novel crystalline pharmaceutical product |
GB0523251D0 (en) * | 2005-11-15 | 2005-12-21 | Glaxo Group Ltd | Novel compounds |
GB0615108D0 (en) * | 2006-07-28 | 2006-09-06 | Glaxo Group Ltd | Novel formulations |
UA116622C2 (uk) | 2011-11-11 | 2018-04-25 | Аллерган, Інк. | Похідні 4-прегенен-11ss-17-21-тріол-3,20-діону для лікування хвороб очей |
CN116135871A (zh) * | 2021-11-16 | 2023-05-19 | 石家庄迪斯凯威医药科技有限公司 | 一种具有抗耐药性的抗菌化合物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1668079B2 (de) | 1968-01-18 | 1976-09-16 | Hoechst Ag, 6000 Frankfurt | Dialkylorthocarbonate von 17alpha, 21-dihydroxysteroiden und verfahren zu ihrer herstellung |
DE2735110A1 (de) * | 1977-08-04 | 1979-02-15 | Hoechst Ag | Corticoid-17-alkylcarbonate und verfahren zu ihrer herstellung |
DE2817988A1 (de) * | 1978-04-25 | 1979-11-08 | Hoechst Ag | Corticoid 17-alkylcarbonate und verfahren zu deren herstellung |
SE449106B (sv) * | 1980-07-10 | 1987-04-06 | Otsuka Pharma Co Ltd | Steroid med anti-inflammatorisk verkan samt komposition innehallande denna |
AU558725B2 (en) * | 1983-09-07 | 1987-02-05 | Mitsubishi Kasei Corporation | Corticoid derivatives |
-
1990
- 1990-08-10 DE DE4025342A patent/DE4025342A1/de not_active Withdrawn
-
1991
- 1991-02-22 TW TW080101348A patent/TW203056B/zh active
- 1991-08-08 EG EG47991A patent/EG19928A/xx active
- 1991-08-08 IL IL9913591A patent/IL99135A/en not_active IP Right Cessation
- 1991-08-08 CZ CS912461A patent/CZ279875B6/cs unknown
- 1991-08-08 HU HU912643A patent/HU211994B/hu not_active IP Right Cessation
- 1991-08-08 PT PT98605A patent/PT98605A/pt not_active Application Discontinuation
- 1991-08-08 FI FI913775A patent/FI913775A/fi not_active Application Discontinuation
- 1991-08-08 EP EP19910113338 patent/EP0470617A3/de not_active Ceased
- 1991-08-08 RU SU915001317A patent/RU2060997C1/ru active
- 1991-08-09 ZA ZA916291A patent/ZA916291B/xx unknown
- 1991-08-09 MX MX9100613A patent/MX9100613A/es not_active IP Right Cessation
- 1991-08-09 NO NO91913115A patent/NO913115L/no unknown
- 1991-08-09 JP JP3223670A patent/JPH0641187A/ja active Pending
- 1991-08-09 IE IE282791A patent/IE912827A1/en unknown
- 1991-08-09 CA CA002048841A patent/CA2048841A1/en not_active Abandoned
- 1991-08-09 KR KR1019910013758A patent/KR920004407A/ko not_active Application Discontinuation
- 1991-08-09 AU AU82560/91A patent/AU646066B2/en not_active Ceased
-
1993
- 1993-02-08 US US08/015,041 patent/US5362721A/en not_active Expired - Fee Related
- 1993-05-07 LV LVP-93-302A patent/LV10459B/en unknown
- 1993-06-25 LT LTIP709A patent/LT3374B/lt not_active IP Right Cessation
-
1994
- 1994-02-28 EC EC1994001049A patent/ECSP941049A/es unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP941049A (es) | 1994-11-16 |
HUT59155A (en) | 1992-04-28 |
LTIP709A (en) | 1995-01-31 |
EP0470617A3 (en) | 1992-04-01 |
IL99135A (en) | 1995-12-08 |
EG19928A (en) | 1996-07-31 |
NO913115D0 (no) | 1991-08-09 |
CS246191A3 (en) | 1992-03-18 |
AU8256091A (en) | 1992-02-13 |
FI913775A (fi) | 1992-02-11 |
HU211994B (en) | 1996-01-29 |
LT3374B (en) | 1995-08-25 |
NO913115L (no) | 1992-02-11 |
KR920004407A (ko) | 1992-03-27 |
LV10459A (lv) | 1995-02-20 |
CA2048841A1 (en) | 1992-02-11 |
HU912643D0 (en) | 1992-01-28 |
CZ279875B6 (cs) | 1995-07-12 |
DE4025342A1 (de) | 1992-02-13 |
IE912827A1 (en) | 1992-02-12 |
MX9100613A (es) | 1992-04-01 |
PT98605A (pt) | 1992-06-30 |
EP0470617A2 (de) | 1992-02-12 |
IL99135A0 (en) | 1992-07-15 |
FI913775A0 (fi) | 1991-08-08 |
JPH0641187A (ja) | 1994-02-15 |
AU646066B2 (en) | 1994-02-03 |
RU2060997C1 (ru) | 1996-05-27 |
TW203056B (lv) | 1993-04-01 |
ZA916291B (en) | 1992-04-29 |
US5362721A (en) | 1994-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LV10459B (en) | Corticued-17-alkylcarbonates, substituted in the 17-position, process for their preparation and pharmaceuticals containing them | |
US4242334A (en) | Corticoid 17-(alkyl carbonates) and processes for their preparation | |
IE48328B1 (en) | Corticoid-17-(alkyl carbonates),process for their manufacture,pharmaceutical compositions containing them and their use in the treatment of inflammatory dermatitis | |
Ueno et al. | Synthesis and evaluation of antiinflammatory activities of a series of corticosteroid 17. alpha.-esters containing a functional group | |
PL186637B1 (pl) | Pochodne androstenu, kompozycje farmaceutyczne zawierające je oraz ich zastosowanie | |
US5091380A (en) | N-monosubstituted adamantyl/norbornanyl 17β-carbamides of 3-carboxy-androst-3,5-dienes as testosterone 5α-reductase inhibitors | |
JPH08508278A (ja) | 新規プレドニソロン誘導体 | |
HU186965B (en) | Process for producing new 6-alpha-methyl-prednisolone derivatives | |
JPH02268195A (ja) | 17位置にアミノ置換鎖を有する新規の3―ケトステロイド、それらの製造方法及びこの方法の中間体、それらの薬剤としての使用並びにそれらを含有する製薬組成物 | |
JPH07165788A (ja) | コルチコイド17,21−ジカルボン酸エステルおよびコルチコステロイド17−カルボン酸エステル21−炭酸エステル、それらの製法およびこれらの化合物を含有する医薬 | |
JPS6411037B2 (lv) | ||
KR100450854B1 (ko) | α-17치환체가없는신규의프레그난유도체,이들의의약용도,제조방법,및이의중간체및관련화합물 | |
FI57114C (fi) | Foerfarande foer framstaellning av nya vid cancerterapi anvaendbara terapeutiskt vaerdefulla enolestrar av steroider | |
NO165679B (no) | Analogifremgangsmaate for fremstilling av nye, terapeutiskvirksomme androstan-17beta-karboksyl-syreestere. | |
US5196411A (en) | 17β-acyl-3-carboxy-androsta-3,5-dienes as testosterone 5α-reductase inhibitors | |
US4176126A (en) | Novel corticoids | |
US5075450A (en) | Intermediates in the synthesis of 17β-acyl-3-carboxy-androsta-3,5-dienes | |
JP2007507467A (ja) | 誘導性noシンターゼ阻害剤としてのイミダゾピリジン誘導体 | |
JPH0592989A (ja) | テストステロン 5α−還元酵素阻害剤としての17β−アシル−3−カルボキシ−アンドロスタ−3,5−ジエン類 | |
HU208152B (en) | Process for producing 19-norprogesterone derivatives alkylated in 17/21-position and pharmaceutical compositions comprising such compounds | |
PT708111E (pt) | 21 ¬0|-esteres de 17-desoxicorticosteroides processo para a sua preparacao e medicamento que os contem | |
US4079054A (en) | 7α-Halogeno-3-oxo-1,4-pregnadiene-21,17β-carbolactones and related compounds | |
JPH046200B2 (lv) | ||
KR810000582B1 (ko) | 코르티코이드 17-(알킬 카보네이트)류의 제조방법 | |
KR830000084B1 (ko) | 코르티코이드-17-(알킬 카보네이트)의 제조방법 |